Top Markets
Coin of the day
Silverback Therapeutics, Inc. Silverback Therapeutics, Inc.

Silverback Therapeutics, Inc.

SBTX
Rank in Stocks #12787
Silverback Therapeutics, Inc. operates as a biotechnology firm dedicated to... Silverback Therapeutics, Inc. operates as a biotechnology firm dedicated to devising tissue-specific drug candidates aimed at addressing chronic viral infections, various cancers, and other significant medical conditions. Among its pipeline, SBT8230 stands out as a treatment for chronic hepatitis B virus, working by stimulating an antiviral immune response through the precise activation of TLR8 within the liver. The company was founded in 2016 and maintains its principal offices in Seattle, Washington.
Share Price
$5.87
Last synced: 2022-11-08
Market Cap
$550.43M
Change (1 day)
1.03%
Change (1 year)
0.00%
Country
US
Trade Silverback Therapeutics, Inc. (SBTX)

Category

Earnings for Silverback Therapeutics, Inc. (SBTX)
Earnings in 2026 TTM: 0
According to Silverback Therapeutics, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Silverback Therapeutics, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$1.95B -
NL
$-4.02B -
AU
$-3.09B -
US
- -
CH